Overview

Bioequivalence of Tablet Formulation 3 (TF3) and Tablet Formulation 2 (TF2) and Effect of Food on the Pharmacokinetics (PK) of Tepotinib

Status:
Completed

Trial end date:
2019-01-25

Target enrollment:

Participant gender:

Summary

The study will demonstrate bioequivalence between the new tablet formulation (TF3, test treatment) and the tablet formulation used in clinical studies (TF2, reference treatment) and will investigate effect of food on PK of tepotinib.

Phase:

Phase 1

Details

Lead Sponsor:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Tepotinib